Skip to content

Efficacy of Autologous Plateletpheresis in Adult Aortic Surgery

Efficacy of Autologous Plateletpheresis in Adult Aortic Surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200065834
Enrollment
Unknown
Registered
2022-11-16
Start date
2022-11-15
Completion date
Unknown
Last updated
2023-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aorta Disease

Interventions

Autologous platelet collection group:After the establishment of central vein catheter and before heparinization, blood component separator (Fresenius Kabi, COM. TEC) was used to collect platelets.
Control group:N/A

Sponsors

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients scheduled to undergo aortic surgery under extracorporeal circulation at Fuwai Hospital from September 1, 2022 to December 31, 2024. These patients may receive allogeneic platelet transfusion during surgery; 2. Patients aged 18-65 years old and weighing more than 50 kg; 3. Patients with platelet count >= 150 x 10^9 /L and < 450 x 10^9/L before surgery; 4. Patients who stopped taking antiplatelet drugs for more than 5 days, or laboratory tests confirmed no platelet dysfunction; 5. The above patients must meet both cardiac surgery and anesthesia criteria and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients was complicated with other heart, lung and brain diseases, infections, clinically diagnosed severe liver and kidney insufficiency, clinically diagnosed abnormal coagulation function; patients can't cooperate with research, such as language comprehension, mental illness, etc; 2. Patients who have received platelet collection within 15 days; 3. Patients with cardiogenic shock, cardiac arrest, and severe hypotension before surgery; 4. Patients who refuse blood transfusions; 5. Patients who have participated in other drug device clinical trials that have not been completed; 6. Other reasons not considered suitable for inclusion in this study.

Design outcomes

Primary

MeasureTime frame
the rate of perioperative pRBC transfusion;

Secondary

MeasureTime frame
the volume of perioperative pRBC transfusion;drainage volume;the incidence of adverse events;

Countries

China

Contacts

Public ContactHongwen Ji

Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Science and Peking Union Medical College

jihongwen@fuwai.com+86 137 0122 9553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026